ABSTRACTS POSTER SESSION
P.12 PRIMARY OVARIAN CARCINOMA: AN UNUSUAL EXTRA-MAMMARY TUMOR METASTASIZING TO THE BREAST: A RETROSPECTIVE ANALYSIS
G. El Hachem, L. Polastro, J. Kerger
P.03 THE TRITON CLINICAL TRIAL PROGRAMME: EVALUATION OF THE POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY
B. Sautois, J.C. Goeminne, S. Rottey, D. Schrijvers, F. Van Aelst, S. Van Bruwaene, S. Watkins, A. Simmons, J. Go, M. Collins, T. Golsorkhi, W. Abida, C. Ryan, H. Scher, S. Chowdhury
P.04 ENDOTHELIAL CELL METABOLISM BLOCKADE TO INDUCE TUMOR VESSEL NORMALIZATION AND IMPROVE CURRENT IMMUNOTHERAPY
V. Geldhof, A.R. Cantelmo, P. Carmeliet
P.05 LONG-TERM CLINICAL OUTCOME AND SURVIVORSHIP ISSUES OF HIGH GRADE BONE SARCOMAS
C. Closset, T. Gil, Martine Piccart, M.J. Piccart-Gebhart
P.06 THE IMPACT OF NETWERK ON THE MULTIDISCIPLINARY TUMOR BOARDS
T. Vandamme, W. Lybaert, M. Simoens, W. Demey, T. Rondou, P. Abrams, C. Mattelaer, B. Op De Beeck, O. D’Archambeau, G. Roeyen, L. De Backer, Marc Peeters, Steering Committee, NET-specialists
P.07 EXCELLENT SURVIVAL OUTCOMES FOR NET PATIENTS TREATED WITHIN NETWERK, A COLLABORATIVE ENETS CENTER OF EXCELLENCE
T. Vandamme, I. Maurissen, W. Lybaert, M. Simoens, P. Abrams, A. Driessen, B. Op De Beeck, W. Demey, T. Rondou, M. Ulenaers, G. Vanhoutte, M. Peeters, Steering Commitee, NET-specialists
P.08 AUTOIMMUNE POLYARTHRITIS: A RARE COMPLICATION OF RENAL CLEAR CELL CARCINOMA ON IMMUNOTHERAPY
X. Wang, G. El Hachem, W. Bekolo, L. Dal Lago, A. Georgala, T. Pepersack, S. Aspeslagh, L. Buisseret, T. Gil, A. Awada
P.09 BRAIN METASTASIS: AN UNUSUAL DISSEMINATION OF EXTRA-OSSEOUS EWING SARCOMA
G. El Hachem, C. Jungels
P.10 PRECLINICAL CDK4/6 INHIBITION FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
V. Caloen
P.11 A-146 LONG TERM RESPONSE WITH COMBINATION IMMUNOTHERAPY IN A PATIENT WITH SYMPTOMATIC MELANOMA BRAIN METASTASES
T. Wessels, J. Mebis
P.02 THE ROLE OF TOPOISOMERASE II-A (TOPO IIA) AS A PREDICTIVE FACTOR FOR RESPONSE TO NEOADJUVANT ANTHRACYCLINES BASED CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER
M. Gamea
P.13 UNEXPECTED TOXICITY IN A PATIENT TREATED WITH FLUOROPYRIMIDINES FOR A METASTATIC BREAST CANCER
Y. Wissam, C. Hanssens, Y. Lalami, A. Georgala, A. Awada
P.14 METASTATIC MELANOMA: CURED BY SURGERY OR DELAYED IMMUNOTHERAPY RESPONSE
E. Roets, K. Tukanova, A. Govarts, P. Specenier
P.15 ABOUT A COMBINATION OF LOWER ESOPHAGEAL CANCER AND SECONDARY CEREBRAL LOCALIZATION
F. Djema, A. Awada
P.16 ABOUT A CASE: MALE BREAST CANCER WITH PULMONARY METASTASES AND THERAPEUTIC RESPONSE TO EVEROLIMUS+EXEMESTANE
F. Djema, A. Awada
P.17 PROGRAMMED CELL DEATH-1 (PD-1) INHIBITORS: DON’T FORGET TYPE 1 DIABETES MELLITUS! A CASE REPORT
K. Janssens, K. Clotman, P. Specenier, C. De Block
P.18 QUALITY OF LIFE, FATIGUE, AND SUBJECTIVE COGNITIVE FUNCTIONING IMMEDIATELY AND 6 MONTHS AFTER ADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
J. Mebis, S. Censabella, S. Engels, C. Van Narsenille, G. Orye, S. Marquette, L. Vansteelant, L. Noé, A. Maes, P. Bulens, E.J.R. Joosens, D. Luyten
P.19 A-105 WHEN DRUG TOXICITIES ARE DRIVEN BY SOCIAL HABITS: A CASE REPORT
Y. Jounblat, G. El Hachem, A. Drowart, J. Kerger
P.10 PULMONARY SARCOID-LIKE GRANULOMATOSIS INDUCED BY PEMBROLIZUMAB IN A PATIENT WITH MELANOMA
I. Bold, J. Kerger, B. Grigoriu
P.01 A LUNG CANCER-DERIVED CRAF MUTATION IS ERK PATHWAY ACTIVATING AND PREDICTS SENSITIVITY TO COMBINED TYPE II RAF AND MEK INHIBITION
A. Noeparast, J. De Grève, S. De Brakeleer, P. Giron, C. Eggermont, R.B. Shahi, E. Teugels
ABSTRACTS PROFFERED PAPER SESSION
O.03 DETECTION OF AR PERTURBATIONS IN CIRCULATING TUMOUR CELLS AND CELL-FREE DNA FROM PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREDICTS RESISTANCE TO ENDOCRINE THERAPY
B. De Laere, M. Mayrhofer, T. Whitington, P-J. Van Dam, P. Van Oyen, C. Ghysel, J. Ampe, P. Ost, W. Demey, L. Hoekx, D. Schrijvers, B. Brouwers, W. Lybaert, E. Everaert, P. Van Kerckhove, D. De Maeseneer, M. Strijbos, A. Bols, K. Fransis, N. Beije, I. De Kruijff, S. Oeyen, A. Rutten, V. Van Dam, A. Brouwer, D. Goossens, L. Heyrman, G. Van Den Eynden, J. Vandebroek, J. Del-Favero, S. Sleijfer, A. Uhlen, J. Yachnin, S. Van Laere, H. Grönberg, J. Lindberg, L. Dirix
O.01 IDENTIFICATION, CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) MUTATIONS IN METASTATIC BREAST CANCER PATIENTS
L. Jongen, G. Floris, D. Lambrechts, A. Laenen, P. Neven, G. Mann, R. Cutler Jr., A. Lalani, H. Wildiers
O.02 REAL-LIFE TREATMENT PRACTICE FOR MALIGNANT PLEURAL MESOTHELIOMA IN BELGIUM
M. Rosskamp, G. Macq, K. Nackaerts, M. Praet, L. Van Eycken, J. Van Meerbeeck, H. De Schutter
O.04 PLOCABULIN, A TUBULIN INHIBITOR, HAS ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF GASTROINTESTINAL STROMAL TUMOR (GIST)
Y. Wang, A. Wozniak, J. Wellens, Y.K. Gebreyohannes, M.J. Guillén, C.M. Galmarini, P.M. Avilés, M. Debiec-Rychter, R. Sciot, P. Schöffski
O.05 MT4-MMP, EGFR AND RB EXPRESSIONS ARE PREDICTIVE BIOMARKERS OF RESPONSE TO ERLOTINIB-PALBOCICLIB COMBINATION IN TRIPLE NEGATIVE BREAST CANCERS
P. Foidart, N-E. Sounni, G. Jerusalem
O.06 PHOTOBIOMODULATION THERAPY FOR THE PREVENTION OF ACUTE RADIATION DERMATITIS: PRELIMINARY RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN BREAST CANCER PATIENTS
J. Robijns, S. Censabella, S. Claes, L. Pannekoeke, L. Bussé, D. Colson, I. Kaminski, A. Maes, P. Bulens, M. Brosens, L. Noé, I. Lambrichts, A. Timmermans, V. Somers, J. Mebis
O.07 EFFECT OF MINDFULNESS TRAINING ON QUALITY OF LIFE AND DISTRESS IN CANCER PATIENTS
J. Mebis, S. Censabella, S. Engels, G. Orye, S. Marquette, C. Van Narsenille, L. Vansteelant, Leen Noe, A. Maes, Paul Bulens, Daisy Luyten, E.J.R. Joosens
O.08 ULTRA-DEEP TARGETED RESEQUENCING REVEALS RECURRENT DAXX AND CYFIP2 MUTATIONS AND IMPLICATES NOVEL PATHWAYS IN PANCREATIC NEUROENDOCRINE TUMORS
T. Vandamme, M. Beyens, G. Van Camp, G. Boons, L. Hofland, M. Peeters, K. Op de Beeck
O.09 GLIOBLASTOMA MULTIFORME (GBM): STUPP AND REALITY
N. van den Eede, P. Specenier, A. de Paepe
O.10 THE DEUBIQUITINASE USP13 AS A NOVEL THERAPEUTIC CO-TARGET IN EGFR MUTANT NON-SMALL CELL LUNG CANCER
P. Giron, C. Eggermont, E. Teugels, G. Gutierrez, J. De Grève
Top
